business news
Myrexis and Gilead Sciences Among Most Active Stocks in Nasdaq Pre-Market
By
Christopher Witrak
Nov 12, 2012 9:25 am
Clovis Oncology was down this morning.
PRINT
-
Stay Connected
-
-
-
-
MINYANVILLE ORIGINAL The three most active funds and stocks in pre-market trading on the Nasdaq (INDEXNASDAQ:.IXIC) were Myrexis (NASDAQ:MYRX), Gilead Sciences (NASDAQ:GILD), and Clovis Oncology (NASDAQ:CLVS) as of 9:15 a.m. EST.
Investors traded 2,098,200 shares of Myrexis, which was up $0.42, or 17.95%. Reuters reported today that the board of directors of Myrexis have decided to dissolve the biopharmaceutical company. Shareholders will receive approximately between $72.9 million and $77.9 million, or between $2.72 and $2.91 per share.
Investors exchanged 1,435,288 shares of Gilead Sciences, which was up $7.47, or 11.49%. According to Bloomberg, a combination of Gilead's experimental hepatitis C therapies removed the virus in 100% of patients in trial.
Investors also traded 563,272 shares of Clovis Oncology, which was down $8.74, or 40.67%. Clovis' experimental drug for pancreatic cancer, CP-4126, failed in a late stage trial. The company has suspended all development of the drug.
Twitter: @ChrisWitrak
Investors traded 2,098,200 shares of Myrexis, which was up $0.42, or 17.95%. Reuters reported today that the board of directors of Myrexis have decided to dissolve the biopharmaceutical company. Shareholders will receive approximately between $72.9 million and $77.9 million, or between $2.72 and $2.91 per share.
Investors exchanged 1,435,288 shares of Gilead Sciences, which was up $7.47, or 11.49%. According to Bloomberg, a combination of Gilead's experimental hepatitis C therapies removed the virus in 100% of patients in trial.
Investors also traded 563,272 shares of Clovis Oncology, which was down $8.74, or 40.67%. Clovis' experimental drug for pancreatic cancer, CP-4126, failed in a late stage trial. The company has suspended all development of the drug.
Twitter: @ChrisWitrak
No positions in stocks mentioned.
